Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Approval crawled time : 13:20 save search
Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada
Published: 2023-07-20 (Crawled : 13:20) - globenewswire.com
ATOS | $1.37 -3.52% -3.65% 1.2M
|
Health Technology
|
| O: 4.67%
H: 2.68%
C: 1.79%
health approval canada trial therapeutics phase 2
argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
Published: 2023-06-30 (Crawled : 13:20) - globenewswire.com
ZLAB | News | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: 0.19%
H: 5.92%
C: 4.64%
ARGX | $360.11 0.47% 0.47% 330K
|
Health Technology
|
| O: 0.91%
H: 1.21%
C: 0.85%
vyvgart approval china
TG Therapeutics Announces European Commission Approval for BRIUMVI® (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
Published: 2023-06-01 (Crawled : 13:20) - globenewswire.com
TGTX | News | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: 0.45%
H: 5.5%
C: 2.49%
briumvi approval sclerosis treatment therapeutics
Akebia Announces UK MHRA Approval of Vafseo® (vadadustat) for the Treatment of Symptomatic Anemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis
Published: 2023-05-22 (Crawled : 13:20) - biospace.com/
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
|
| O: 8.62%
H: 29.37%
C: 11.9%
vafseo disease kidney anemia approval treatment dialysis
Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for TEPEZZA® (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease Activity or Duration
Published: 2023-04-14 (Crawled : 13:20) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.25%
H: 1.1%
C: 0.54%
tepezza fda disease approval update thyroid eye therapeutics
Takeda Receives FDA Approval to Expand the Use of HYQVIA® to Treat Primary Immunodeficiency in Children
Published: 2023-04-11 (Crawled : 13:20) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.36%
H: 0.35%
C: -0.12%
hyqvia fda children approval
PPL Corporation subsidiary Rhode Island Energy gains regulatory approval for $290 million to strengthen network safety, reliability and resilience
Published: 2023-03-30 (Crawled : 13:20) - prnewswire.com
PPL | News M | $27.02 1.5% 0.0% 4.9M
|
Utilities
|
| O: 0.4%
H: 0.49%
C: -0.33%
energy approval corporation network
Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
Published: 2023-03-27 (Crawled : 13:20) - biospace.com/
OCGN | News A | $1.315 -0.38% -0.38% 6.5M
|
Health Technology
|
| O: 1.3%
H: 0.38%
C: -5.2%
ocu400 fda approval treatment ongoing trial
argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis
Published: 2023-03-15 (Crawled : 13:20) - globenewswire.com
ARGX | $360.11 0.47% 0.47% 330K
|
Health Technology
|
| O: -1.66%
H: 1.77%
C: 1.37%
treatment vyvgart approval
Crescent Point Receives Approval for Normal Course Issuer Bid
Published: 2023-03-07 (Crawled : 13:20) - prnewswire.com
CPG | $8.69 2.84% -0.92% 5.5M
|
Energy Minerals
|
| O: -0.14%
H: 1.1%
C: -3.17%
crescent approval
Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
Published: 2023-01-31 (Crawled : 13:20) - biospace.com/
CNTX | $1.39 -1.42% -1.44% 5.7K
|
Health Technology
|
| O: 78.62%
H: 27.05%
C: -13.11%
fda breast approval cancer group elascestrant orserdu ona-xr her2- her2
HomeTrust Bancshares, Inc. Announces Regulatory Approval for Merger with Quantum Capital Corp.
Published: 2023-01-31 (Crawled : 13:20) - globenewswire.com
HTBI | $24.305 1.48% 1.46% 49K
|
Finance
|
| O: -0.79%
H: 1.85%
C: 1.85%
quantum approval
Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO
Published: 2023-01-24 (Crawled : 13:20) - biospace.com/
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: -0.15%
H: 18.49%
C: 15.32%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.15%
H: 0.18%
C: -0.48%
candidate application trial approval therapeutics therapy
SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center
Published: 2023-01-18 (Crawled : 13:20) - biospace.com/
SPRC | $1.235 -4.26% -4.45% 150K
|
Manufacturing
|
| O: 0.93%
H: 6.48%
C: -5.56%
children medical trial approval
MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan
Published: 2022-12-23 (Crawled : 13:20) - globenewswire.com
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: 0.55%
H: 6.18%
C: 4.45%
global japan approval
Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients
Published: 2022-12-08 (Crawled : 13:20) - biospace.com/
BIXT | $0.1285 490.75% 32K
|
Professional, Scientific, and T...
|
| O: 4.78%
H: 0.0%
C: 0.0%
covid-19 approval
SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis
Published: 2022-12-01 (Crawled : 13:20) - globenewswire.com
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: -3.39%
H: 1.74%
C: -7.02%
brexafemme fda candidiasis approval
Ingredion Receives SBTi Approval of Its Greenhouse Gas Emissions Reduction Targets
Published: 2022-12-01 (Crawled : 13:20) - globenewswire.com
INGR A | $113.62 1.15% 0.0% 360K
|
Process Industries
|
| O: 0.27%
H: 0.78%
C: -0.18%
approval
Copper Mountain Mining Receives Bondholder Approval for the Sale of the Eva Copper Project and the Australian Exploration Tenements and Announces Bond Buyback Offer
Published: 2022-11-28 (Crawled : 13:20) - prnewswire.com
HMY | $9.29 1.86% 0.0% 6.2M
|
Non-Energy Minerals
|
| O: 1.4%
H: 0.55%
C: -6.63%
approval
Elys Game Technology Granted Conditional License Approval in Ohio
Published: 2022-11-23 (Crawled : 13:20) - globenewswire.com
ELYS | $0.1331 14.4% 58K
|
Consumer Services
|
| O: -4.22%
H: 5.36%
C: -3.21%
license technology granted approval
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.